Thursday 16 October, 2025
Introduction: Prostate cancer, and more specifically metastatic castration-resistant prostate cancer (mCRPC), is a common cancer in men worldwide. Abiraterone acetate…
Read morePoster: Drug/Disease Modelling - Oncology
Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer
Thursday 16 October, 2025
Introduction: Targeting the androgen receptor (AR) continues to be an important therapeutic approach in patients with metastatic castration-resistant prostate cancer (mCRPC)….
Read morePopulation PK-PD modeling and exposure-response analysis in multiple myeloma patients treated with intravenous forimtamig, a T-cell engaging 2:1 bispecific antibody targeting GPRC5D and CD3
Thursday 16 October, 2025
Introduction: Forimtamig is a bispecific T-cell engaging bispecific antibody that redirects T-cells to target and eliminate cells expressing GPRC5D, including…
Read morePopulation pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent
Thursday 16 October, 2025
Objectives: To develop a population pharmacokinetic model for simultaneous interspecies allometric scaling of individual preclinical pharmacokinetics and to predict the…
Read morePopulation pharmacokinetic-based targeted exome sequencing (PopPK-TES) approach to assess the impact of genetic variants on pharmacokinetics of lurbinectedin in patients with advanced cancer
Thursday 16 October, 2025
Objectives: To develop a population pharmacokinetic-based targeted exome sequencing (PopPK-TES) strategy aiming to assess the impact of genetic variants on…
Read morePopulation pharmacokinetic-based, two-stage approach to assess the impact of genetic variants on lurbinectedin exposure in patients with advanced cancer
Thursday 16 October, 2025
Introduction: Lurbinectedin (Zepzelca®) is a selective inhibitor of oncogenic transcription, and has a direct effect on the tumor microenvironment by…
Read moreOptimizing Biomarker-Based Dosing Algorithm for Erdafitinib through PK-PD Modeling and Simulations
Thursday 16 October, 2025
Objectives: To guide a phosphate-based dosing algorithm for erdafitinib, an orally administered panfibroblast growth factor (FGFR) tyrosine kinase inhibitor, using…
Read moreExposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma
Thursday 16 October, 2025
Erdafitinib is an oral, pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in development for the treatment of locally advanced…
Read moreA model-based survival meta-analysis for indirect comparison of immune therapy efficacy in NSCLC
Thursday 16 October, 2025
Introduction: Overall survival (OS) is a key endpoint for the efficacy assessment in oncology clinical trials [1]. However, indirect comparison…
Read moreSimulation based assessment of flat dose regimen of an anti-PDL1 antibody: Case study of avelumab
Thursday 16 October, 2025
Objectives: Avelumab is a human anti–PD-L1 IgG1 antibody that has demonstrated meaningful efficacy and clinical activity across various tumor types…
Read more